Table 2.
Child IXT Symptom Questionnaire Scores Over Time with treatment groups combined.
| Baseline Visit | 6-Month Visit | 12-Month Visit | 18-Month Visit | |
|---|---|---|---|---|
| Child IXT Symptom Score | N = 364 | N = 349 | N = 345 | N = 327 |
| Mean (SD) | 34.9 (17.2) | 29.9 (16.8) | 28.3 (15.7) | 28.7 (15.8) |
| Median (IQR) |
37.4 (25.7, 46.1) |
32.2 (15.7, 42.0) |
32.2 (15.7, 37.4) |
32.2 (15.7, 37.4) |
| Range | 0 to 99.9 | 0 to 99.9 | 0 to 74.5 | 0 to 74.5 |
| Change from Baseline | N = 335 | N = 332 | N = 310 | |
| Mean (SD)a | n/a | −5.3 (17.8) | −6.6 (18.9) | −5.7 (20.8) |
| 95% CI for Mean Changea | n/a | (−7.2, −3.4) | (−8.6, −4.6) | (−8.1, −3.4) |
| Effect Sizeb | n/a | 0.30 | 0.35 | 0.28 |
IXT = intermittent exotropia; SD = standard deviation; IQR = interquartile range; CI = confidence interval
a
The paired t-test was used to estimate mean changes from baseline to follow-up visits and the 95% CIs for the 0–100 scores. P-values were not reported.
b
This is the absolute value of the effect size for the overall improvement from baseline. First, the 0–100 score at baseline was subtracted from the 0–100 score at each follow-up visit for each participant. Then, this change from baseline was averaged across all participants; this average was divided by the standard deviation of the changes to calculate the effect size.